Zobrazeno 1 - 10
of 122
pro vyhledávání: '"tessa holyoake"'
Autor:
Jan Cools
Publikováno v:
HemaSphere, Vol 1, Iss 1 (2017)
Externí odkaz:
https://doaj.org/article/e0102ee5504e4ccabdb9e05d78542139
Autor:
Jan Cools
Publikováno v:
HemaSphere
HemaSphere, Vol 1, Iss 1 (2017)
HemaSphere, Vol 1, Iss 1 (2017)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21f03457614bbe24512ae9a826241d86
https://pubmed.ncbi.nlm.nih.gov/31723740
https://pubmed.ncbi.nlm.nih.gov/31723740
Autor:
Cools J; VIB, Center for Cancer Biology.; KU Leuven, Center for Human Genetics, KU Leuven, Leuven, Belgium.
Publikováno v:
HemaSphere [Hemasphere] 2017 Dec 20; Vol. 1 (1), pp. e11. Date of Electronic Publication: 2017 Dec 20 (Print Publication: 2017).
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
BMJ. :j4224
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::40504eab2441b1da0075762db31fedcd
https://doi.org/10.1136/bmj.j4224
https://doi.org/10.1136/bmj.j4224
Autor:
Anne-Louise Latif, Ashley Newcombe, Sha Li, Kathryn Gilroy, Neil A. Robertson, Xue Lei, Helen J. S. Stewart, John Cole, Maria Terradas Terradas, Loveena Rishi, Lynn McGarry, Claire McKeeve, Claire Reid, William Clark, Joana Campos, Kristina Kirschner, Andrew Davis, Jonathan Lopez, Jun-ichi Sakamaki, Jennifer P. Morton, Kevin M. Ryan, Stephen W. G. Tait, Sheela A. Abraham, Tessa Holyoake, Brian Higgins, Xu Huang, Karen Blyth, Mhairi Copland, Timothy J. T. Chevassut, Karen Keeshan, Peter D. Adams
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-16 (2021)
MDM2 and BET inhibitors have shown efficacy in AML treatment. Here, the authors show that the two compounds can synergize through both p53 protein stabilization and inhibition of BRD4-mediated repression of p53 target genes.
Externí odkaz:
https://doaj.org/article/4058dbf2924543a399c2f17c8fd2a6ad
Autor:
Eduardo Gómez-Castañeda, Simon Rogers, Chinmay Munje, Joana Bittencourt-Silvestre, Mhairi Copland, David Vetrie, Tessa Holyoake, Lisa Hopcroft, Heather Jørgensen
Publikováno v:
Cancers; Volume 14; Issue 21; Pages: 5253
2AbstractTyrosine kinase inhibitors (TKI) have revolutionised the treatment of CML. However, TKI do not eliminate the leukaemia stem cells (LSC), which can reinitiate the disease. Thus, finding new therapeutic targets in CML LSC is key to finding a c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::877d404047d2eb40e6eb52dd441b3bb7
https://pubmed.ncbi.nlm.nih.gov/36358672
https://pubmed.ncbi.nlm.nih.gov/36358672
Publikováno v:
BMJ (British Medical Journal); 2017, Vol. 358 Issue: 9 pj4224-j4224, 1p
Autor:
Richard A. Van Etten, Steffen Koschmieder, Francois Delhommeau, Danilo Perrotti, Tessa Holyoake, Animesh Pardanani, Ruben Mesa, Tony Green, Amr R. Ibrahim, Tariq Mughal, Robert Peter Gale, John Goldman
Publikováno v:
Haematologica, Vol 96, Iss 4 (2011)
This review focuses on topical issues in the biology and treatment of the myeloproliferative neoplasms (MPNs). Studies in transgenic mice suggest that BCR-ABL1 reduces the fraction of self-renewing ‘leukemic’ stem cells in the bone marrow but tha
Externí odkaz:
https://doaj.org/article/34f649a2185b47bd9d3339711691443b
Publikováno v:
PLoS Computational Biology, Vol 5, Iss 9, p e1000503 (2009)
Imatinib mesylate induces complete cytogenetic responses in patients with chronic myeloid leukemia (CML), yet many patients have detectable BCR-ABL transcripts in peripheral blood even after prolonged therapy. Bone marrow studies have shown that this
Externí odkaz:
https://doaj.org/article/a3a728b03e7e499091e3e993abeb518a